NPCE · Company research
Neuropace, Inc. (NPCE): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
19records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| NeuroPace, Inc. (NPCE) - What Are Brokerages Saying About This Stock? - MarketBeat | NeuroPace, Inc. (NPCE) - What Are Brokerages Saying About This Stock? MarketBeat | View source ↗ | MarketBeat | Oct 18, 2026 | neutral | 0 | 0.6 |
| The Technical Signals Behind (NPCE) That Institutions Follow - Stock Traders Daily | The Technical Signals Behind (NPCE) That Institutions Follow Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 13, 2026 | neutral | 0 | 0.6 |
| Global Bioelectronic Medicine Market Anticipates Impressive Growth Trajectory of ~10% by 2034 | DelveInsight | The global bioelectronic medicine market is projected to grow from USD 8.9 billion in 2025 to USD 21.6 billion by 2034, driven by increasing adoption of neuromodulation technologies, advances in implantable devices, AI integration, and expanding applications beyond neurological disorders. North America leads the market with 44% share, while Asia-Pacific is expected to record the fastest growth rate. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bullish | 1 | 1 |
| Global Bioelectronic Medicine Market Anticipates Impressive Growth Trajectory of ~10% by 2034 | DelveInsight | The global bioelectronic medicine market is projected to grow from USD 8.9 billion in 2025 to USD 21.6 billion by 2034, driven by increasing adoption of neuromodulation technologies, advances in implantable devices, AI integration, and expanding applications beyond neurological disorders. North America leads the market with 44% share, while Asia-Pacific is expected to record the fastest growth rate. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bullish | 1 | 1 |
| Trading Systems Reacting to (NPCE) Volatility - Stock Traders Daily | Trading Systems Reacting to (NPCE) Volatility Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 3, 2026 | neutral | 0 | 0.6 |
| Neuropace Inc (NPCE-Q) Stock Price and News - The Globe and Mail | Neuropace Inc (NPCE-Q) Stock Price and News The Globe and Mail | View source ↗ | The Globe and Mail | Oct 1, 2026 | neutral | 0 | 0.6 |
| After shares were withheld for taxes, NeuroPace (NPCE) medical chief Martha Morrell held 51,357 shares. - Stock Titan | After shares were withheld for taxes, NeuroPace (NPCE) medical chief Martha Morrell held 51,357 shares. Stock Titan | View source ↗ | Stock Titan | Sep 25, 2026 | neutral | 0 | 0.6 |
| (NPCE) Volatility Zones as Tactical Triggers - Stock Traders Daily | (NPCE) Volatility Zones as Tactical Triggers Stock Traders Daily | View source ↗ | Stock Traders Daily | Sep 22, 2026 | neutral | 0 | 0.6 |
| NeuroPace (NPCE) CFO has 1,162 shares withheld for taxes - Stock Titan | NeuroPace (NPCE) CFO has 1,162 shares withheld for taxes Stock Titan | View source ↗ | Stock Titan | Sep 21, 2026 | neutral | 0 | 0.6 |
| Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report? - Yahoo Finance | Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report? Yahoo Finance | View source ↗ | Yahoo Finance | Sep 10, 2026 | neutral | 0 | 0.6 |
| NeuroPace (NPCE) Dips 1.49% to $14.54, Positioned Midway Between $13.81 Support and $15.27 Resistance - Value Area High - siam.in | NeuroPace (NPCE) Dips 1.49% to $14.54, Positioned Midway Between $13.81 Support and $15.27 Resistance - Value Area High siam.in | View source ↗ | siam.in | Sep 9, 2026 | neutral | 0 | 0.6 |
| NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity? - TradingView | NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity? TradingView | View source ↗ | TradingView | Aug 17, 2026 | neutral | 0 | 0.6 |
| NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up - Yahoo Finance | NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up Yahoo Finance | View source ↗ | Yahoo Finance | Aug 12, 2026 | neutral | 0 | 0.6 |
| FDA Asks NeuroPace for More Evidence on Epilepsy Device - Stock Titan | FDA Asks NeuroPace for More Evidence on Epilepsy Device Stock Titan | View source ↗ | Stock Titan | Jul 28, 2026 | neutral | 0 | 0.6 |
| At US$17.80, Is It Time To Put NeuroPace, Inc. (NASDAQ:NPCE) On Your Watch List? - Simply Wall Street | At US$17.80, Is It Time To Put NeuroPace, Inc. (NASDAQ:NPCE) On Your Watch List? Simply Wall Street | View source ↗ | Simply Wall Street | Jul 8, 2026 | neutral | 0 | 0.6 |
| NPCE Forecast — Price Target — Prediction for 2027 - TradingView | NPCE Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| NeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance | NeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound? Yahoo Finance | View source ↗ | Yahoo Finance | Jun 11, 2026 | neutral | 0 | 0.6 |
| Is NPCE Stock a Buy in 2026 After DIXI Exit and Margin Lift? - Yahoo Finance | Is NPCE Stock a Buy in 2026 After DIXI Exit and Margin Lift? Yahoo Finance | View source ↗ | Yahoo Finance | May 27, 2026 | neutral | 0 | 0.6 |
| NPCE Stock Gains on Q1 Earnings & Revenue Beat, 2026 Outlook Raised - Zacks Investment Research | NPCE Stock Gains on Q1 Earnings & Revenue Beat, 2026 Outlook Raised Zacks Investment Research | View source ↗ | Zacks Investment Research | May 13, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.